Baseline Productions

Baseline Productions Current Liabilities

The Current Liabilities of Baseline Productions (BSSP) as of Nov 15, 2026 is 1.59 M USD. In the previous year, Current Liabilities was 1.53 M USD — a change of 4.43% (higher).

Current Liabilities

1.59 MUSD

YoY

4.43%

Last updated:

Current Liabilities of Baseline Productions is 2020 1.59 M USD. Current Liabilities of Baseline Productions was 2019 1.53 M USD. It decreases by 4.43% higher compared to the previous year.

The Baseline Productions Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2010
0.00 USD
Jan 1, 2011
0.00 USD
Jan 1, 2012
1,258.00 USD
Jan 1, 2013
120,840.00 USD
Jan 1, 2014
403,292.00 USD
Jan 1, 2019
1.53 M USD
Jan 1, 2020
1.59 M USD
The Baseline Productions Current Liabilities history
YEARCurrent LiabilitiesYoY
1.59 MUSD+4.43%
1.53 MUSD+278.24%
403,292.00USD+233.74%
120,840.00USD+9,505.72%
1,258.00USD—
0.00USD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Baseline Productions Stock analysis

What does Baseline Productions do? Baseline Productions Inc develops mobile based hardware and software based products. The company focuses on commercialization of its proteins for cancer and infectious disease treatments. Its Irreversible Pepsin Fraction (IPF) technology activates the immune system to fight autoimmune diseases. IPF binds to T-cells and triggers Th1 responses that eliminate infected cells. The firm's lead compound is an IPF suspension for autoimmune disease treatment including cancer, cirrhosis, and Hepatitis C. The product IMMUNE-THERAPEUTIC PROTEIN (ITP) is a therapeutic protein derived from porcine pepsin, which is irreversible, modified, and fractionated to IPF sequence. The company sells its IPF platform technology and ITP product to healthcare providers and pharmaceutical companies. Healthcare providers use IPF for immune system activation in autoimmune disease treatment. Pharmaceutical companies purchase ITP for development into therapeutic applications. The target segments include medical institutions treating autoimmune conditions and drug manufacturers seeking novel protein-based therapies. ITP is specifically indicated for cancer, cirrhosis, and Hepatitis C treatment. Baseline Productions generates revenue through licensing IPF technology and selling ITP therapeutic protein. The IPF platform is sold as a technology solution to partners in the healthcare sector. ITP is marketed as a therapeutic product for direct sale to medical facilities. The company's primary customers are healthcare institutions and pharmaceutical firms interested in immune system-based treatments for autoimmune diseases and infectious conditions. Baseline Productions is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Baseline Productions stock

Current Liabilities of Baseline Productions is 1.59 M USD in 2020.

Current Liabilities of Baseline Productions changed from 1.53 M USD to 1.59 M USD, representing a 4.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Baseline Productions since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Baseline Productions historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Baseline Productions

All Key Metrics — Baseline Productions